Selecting the right clinical trial endpoints is essential for achieving study scientific objectives, regulatory success, investor confidence and efficient trial execution. This panel discussion will explore best practices for determining the optimal strategy to meet these goals, while balancing feasibility and cost. Attendees will also gain insight to selecting and overseeing a CRO partner effectively. Comprised of senior management from a CRO, biotech company, and an endpoint solutions vendor, the panel will provide diverse perspectives. Audience participation and Q&A will be encouraged.
Monday, May 4, 14:30 - 15:15, room Kairo
| Name | Position | Institution |
|---|---|---|
| Todd RUDO | EVP, Chief Medical Officer | CLARIO |
| Name | Position | Institution |
|---|---|---|
| Florian Vogl | Chief Medical Officer | TOLREMO Therapeutics |
| Lewis Cameron | CEO | Evestia Clinical CRO |
| John Ohrn | SVP, Global Partnerships | CLARIO |
| Chris Clendening | SVP, Biotech Operations and Product Management | CLARIO |
Clario generates the richest clinical evidence by fusing deep scientific expertise with the industry's broadest endpoint technology platform.
With nearly 50 years of experience across 30,000+ trials and 870 regulatory approvals, we guide biotechs and CROs through every phase of development — from endpoint strategy and protocol design to global data collection and regulatory submission.
Our integrated solutions spans eCOA, Cardiac Safety, Medical Imaging, Respiratory, and Precision Motion, delivering precise, reliable evidence across all trial models. Your science deserves the right endpoints. Let's talk.
